Treatment modalities for Māori and New Zealand European men with localised prostate cancer

International Journal of Clinical Oncology

Volumn 20, Issue 4, 2015, Pages 814-820

  Obertová, Zuzana ^a   Lawrenson, Ross ^a   Scott, Nina ^b   Holmes, Michael ^c   Brown, Charis ^a   Lao, Chunhuan ^a   Tyrie, Leanne ^c   Gilling, Peter ^d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAIKATO DISTRICT HEALTH BOARD   (New Zealand)

^c WAIKATO HOSPITAL   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Active surveillance; Ethnicity; Radical prostatectomy; Radiotherapy; Watchful waiting

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; COMORBIDITY ASSESSMENT; CONTROLLED STUDY; DISTANT METASTASIS; ETHNIC DIFFERENCE; EUROPEAN; HUMAN; MAJOR CLINICAL STUDY; MALE; MAORI (PEOPLE); NEW ZEALAND; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; VERY ELDERLY; CAUCASIAN; ETHNOLOGY; HEALTH CARE DISPARITY; MIDDLE AGED; OCEANIC ANCESTRY GROUP; PROSTATIC NEOPLASMS; RANDOMIZATION; REGISTER; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTHCARE DISPARITIES; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; OCEANIC ANCESTRY GROUP; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84938739538     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-014-0781-4     Document Type: Article

References (34)

1. Ferlay J, Shin HR, Bray F, et al (2010) GLOBOCAN 2008 v1.2. IARC CancerBase No. 10, International Agency for Research on Cancer, Lyon. http://globocan.iarc.fr. Accessed Jul 2011
2. Ministry of Health (2012) Cancer: new registrations and deaths 2009. Ministry of Health, Wellington
3. Crawford ED (2009) Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 73(Suppl 5A):4–10
4. Johansson JE, Holmberg L, Johansson S et al (1997) Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277:467–471
5. Albertsen PC (2010) The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis. Urology 75:399–405
6. Inquiry into early detection and treatment of prostate cancer (2011) Report of the Health Committee. http://www.parliament.nz/NR/rdonlyres/BBF24956DC6542FFAF65A39F58E96EEA/197797/DBSCH_SCR_5250_Inquiryintoearlydetectionandtreatment.pdf. Accessed Feb 2012
7. Gore JL, Kwan L, Lee SP et al (2009) Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst 101:888–892
8. Ung JO, Richie JP, Chen MH et al (2002) Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 60:458–463
9. Horwich A, Hugosson J, de Reijke T et al (2013) Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 24:1141–1162
10. Prostate Cancer Taskforce (2012) Diagnosis and Management of Prostate Cancer in New Zealand Men: Recommendations from the Prostate Cancer Taskforce. Ministry of Health, Wellington
11. Haynes R, Pearce J, Barnett R (2008) Cancer survival in New Zealand: ethnic, social and geographical inequalities. Soc Sci Med 67:928–937
12. Jeffreys M, Stevanovic V, Tobias M et al (2005) Ethnic inequalities in cancer survival in New Zealand: linkage study. Am J Public Health 95:834–837
13. Obertová Z, Scott N, Brown C et al (2013) Survival disparities between Māori and non-Māori men with non-localised prostate cancer in New Zealand. BJU Int (Suppl) 112:14
14. Sneyd MJ (2008) Ethnic differences in prostate cancer survival in New Zealand: a national study. Cancer Causes Control 19:993–999
15. Hill S, Sarfati D, Blakely T et al (2010) Survival disparities in Indigenous and non-Indigenous New Zealanders with colon cancer: the role of patient comorbidity, treatment and health service factors. J Epidemiol Community Health 64:117–123
16. McKenzie F, Jeffreys M, ‘t Mannetje A et al (2008) Prognostic factors in women with breast cancer: inequalities by ethnicity and socioeconomic position in New Zealand. Cancer Causes Control 19:403–411
17. Stevens W, Stevens G, Kolbe J et al (2008) Ethnic differences in the management of lung cancer in New Zealand. J Thorac Oncol 3:237–244
18. Statistics New Zealand (2007) New Zealand All DHB Estimated Resident Population 2006-2026. Statistics New Zealand, Wellington
19. D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974
20. Charlson ME, Pompei P, Ales K et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383
21. Hall W, Ashesh JB, Ryu JK et al (2005) The impact of age and comorbidity on survival and treatment patterns in prostate cancer: using the Charlson Comorbidity Index to improve outcomes. Prostate Cancer Prostatic Dis 8:22–30
22. Salmond C, King P, Crampton P et al (2006) NZiDep: a New Zealand index of socioeconomic deprivation for individuals. Soc Sci Med 62:1474–1485
23. Ciezki JP, Reddy CA, Kupelian PA et al (2012) Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis. Urology 80:367–373
24. Obertová Z, Lawrenson R, Hodgson F et al (2013) Screening for prostate cancer in New Zealand general practice. J Med Screen 20:49–51
25. Pokorny MR, Scott DJ (2011) Do Maori and Pacific Islander men present with more advanced prostate cancer than European New Zealand men? An analysis of 486 men undergoing biopsy in Auckland. BJU Int 107(Suppl 3):27–32
26. Lawrenson R, Lao C, Obertová Z et al (2014) Management and characteristics of patients with metastatic prostate cancer in a cohort of New Zealand men. Oncology 88:157–163
27. Obertová Z, Scott N, Brown C et al (2014) Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand. BMC Fam Practice 15:145. doi:10.1186/1471-2296-15-145
28. Moses KA, Paciorek AT, Penson DF et al (2010) Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol 28:1069–1074
29. Nambudiri VE, Landrum MB, Lamont EB et al (2012) Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Urology 79:537–545
30. Marr PL, Elkin EP, Arrendondo SA et al (2006) Comorbidity and primary treatment for localized prostate cancer: data from CAPSURE™. J Urol 175:1326–1331
31. Hegney D, Pearce S, Rogers-Clark C et al (2005) Close, but still too far. The experience of Australian people with cancer commuting from a regional to a capital city for radiotherapy treatment. Eur J Cancer Care 14:75–82
32. Brabyn L, Barnett JR (2004) Deprivation and geographic access to general practitioners in rural New Zealand. N Z Med J 117:1–13
33. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localised prostate cancer. JAMA 293:2095–2101
34. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300